Related Experiment Video
Updated: Apr 20, 2026
08:58
Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
Published on: October 31, 2025
862
Pulmonary alveolar proteinosis.
Pneumologia (Bucharest, Romania)
|November 26, 2014
Summary
Pulmonary alveolar proteinosis (PAP) is a rare lung disorder with autoimmune and secondary forms. Diagnosis involves lung lavage and GM-CSF antibody tests, with whole lung lavage as a primary treatment.
Area of Science:
- Pulmonology
- Rare Diseases
- Immunology
Background:
- Pulmonary alveolar proteinosis (PAP) is a rare lung disease defined by surfactant and lipoprotein accumulation in alveoli.
- Autoimmune PAP (90% of cases) involves GM-CSF autoantibodies, while secondary PAP links to other conditions and lacks these antibodies.
- Radiological findings like 'crazy paving' on HRCT can mimic other lung diseases, complicating diagnosis.
Purpose of the Study:
- To summarize the characteristics, diagnosis, and treatment of pulmonary alveolar proteinosis.
- To differentiate between autoimmune and secondary forms of PAP.
- To explore current and potential future therapeutic strategies for PAP.
Main Methods:
- Review of existing literature on pulmonary alveolar proteinosis.
- Analysis of diagnostic criteria including imaging (HRCT) and laboratory tests (BAL, GM-CSF antibodies).
- Evaluation of treatment modalities such as whole lung lavage (WLL), inhaled GM-CSF, and rituximab.
Main Results:
- Autoimmune PAP is characterized by GM-CSF autoantibodies, whereas secondary PAP is antibody-negative and associated with underlying conditions.
- Diagnosis is typically confirmed by bronchoalveolar lavage (BAL) findings and serum GM-CSF antibody detection.
- Whole lung lavage (WLL) achieves remission in approximately 50% of PAP cases.
Conclusions:
- PAP is a heterogeneous disorder requiring accurate diagnosis to guide treatment.
- While WLL is standard, inhaled GM-CSF and rituximab show promise for refractory autoimmune PAP.
- Treatment for secondary PAP must target the underlying condition.
Related Concept Videos
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
16
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
16
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
5.3K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
5.3K
01:18Pulmonary Edema II: Pathophysiology
16
Pulmonary edema is the accumulation of fluid in the interstitial and alveolar spaces of the lungs, impairing gas exchange and oxygen delivery. It may be cardiogenic or noncardiogenic, but both reduce oxygenation and lung compliance.Cardiogenic Pulmonary EdemaCardiogenic edema results from increased hydrostatic pressure in pulmonary capillaries, usually due to left ventricular dysfunction from myocardial infarction, heart failure, or valvular disease. Ineffective cardiac pumping causes blood to...
16
01:10Atelectasis II: Pathophysiology
19
Atelectasis develops when alveoli lose their air and collapse inward. Because lung tissue is naturally elastic, these air sacs shrink rather than remaining open. Collapsed alveoli are no longer ventilated, reducing their role in gas exchange. Blood flow may continue in these regions, creating a ventilation–perfusion mismatch. Clinical findings include decreased breath sounds, dullness to percussion, reduced chest expansion, and decreased tactile fremitus as sound transmission through...
19
01:05Breathing
67.5K
The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
67.5K
01:14Atypical Pneumonia
72
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
72